Global Biosimilar Market (2021 to 2026) – Industry Trends, Share, Size, Growth, Opportunity and Forecasts – ResearchAndMarkets.com

Global Biosimilar Market (2021 to 2026) – Industry Trends, Share, Size, Growth, Opportunity and Forecasts – ResearchAndMarkets.com




Global Biosimilar Market (2021 to 2026) – Industry Trends, Share, Size, Growth, Opportunity and Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Biosimilar Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering.

The biosimilar market reached a value of US$ 7.7 Billion in 2020. This market is currently being driven by a number of factors such as patent expires of blockbuster biological drugs, lower prices, rising prevalence of chronic diseases, and cost-saving initiatives from governments and third-party payers. Catalyzed by these factors, the market is expected to witness strong growth during the next five years.

Biosimilars, also known as follow-on biologics, refers to a biotherapeutic product which is highly similar to a reference biologic drug. It is produced using living organisms or cells and has a complex molecular structure. When the patent of a biologic drug expires, manufacturers resort to the approval from the regulatory authorities so as to start the production of biosimilars. For being labelled as a biosimilar, a biological drug should be proved similar in terms of quality, safety and efficacy. In comparison with generic drugs, biosimilars are expensive as their production process is more complex and requires higher investment in research and development.

Companies Mentioned

  • Novartis
  • Pfizer
  • Teva
  • Celltrion
  • Merck & Co
  • Samsung Bioepis
  • Eli Lilly
  • Biocon
  • Dr. Reddy’s Laboratories
  • Amgen
  • Boehringer Ingelheim

Global Biosimilar Market Drivers/Constraints:

  • Over the years, the patents of several blockbuster biologic drugs have expired and a number of blockbuster drugs are further expected to lose patent protection in the coming years. This is expected to provide tremendous opportunities for biosimilar manufacturers in the near future.
  • Cost-saving initiatives undertaken by governments and third-party payers have encouraged the use of biosimilars over branded biologics, thereby propelling the demand of biosimilars.
  • Some of the other factors bolstering the demand for biosimilars include cost-effectiveness, rising prevalence of chronic diseases (such as autoimmune diseases and cancer) and growing geriatric population.
  • There are some factors hampering the growth of the biosimilars market. This includes negative perception from physicians, patent extensions, lower price differential compared to small-molecule generics, etc.

Companies Mentioned

  • Novartis
  • Pfizer
  • Teva
  • Celltrion
  • Merck & Co
  • Samsung Bioepis
  • Eli Lilly
  • Biocon
  • Dr. Reddy’s Laboratories
  • Amgen
  • Boehringer Ingelheim

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Biosimilar Market – Introduction

4.1 Overview

4.2 WHO and FDA Terminology on Biosimilars

4.3 Biosimilars and Generics

4.4 Biosimilars and Branded Biological Products

5 Why are Biosimilars So Lucrative?

5.1 Patent Expiry of Blockbuster Biological Drugs

5.2 Significant Price Differential between Biosimilars and Innovator Drugs

5.3 Savings for the Government and Third Party Payers

5.4 Rising Prevalence of Lifestyle Diseases

5.5 Incentives for Prescribers, Pharmacists and Patients

5.6 Emergence of New Players in Europe and Emerging Markets

5.7 Increasing Product Differentiation as Manufacturers Tie-Up with Drug Delivery Device Companies

6 Biosimilar Research, Development and Manufacturing

6.1 Research and Development: Biosimilars vs. Innovator Drugs

6.2 Manufacturing: Biosimilars vs. Innovator Drugs

7 Biosimilar Market

8 Market Breakup by Molecule

9 Market Breakup by Type of Manufacturing

10 Market Breakup by Indication

11 Market Breakup by Region

12 Requirements for Setting Up a Biosimilar Manufacturing Plant

13 Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/r/ivlsn8

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900